Sensus Healthcare (NASDAQ:SRTS) Stock Price Passes Below 50-Day Moving Average of $5.13

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $5.13 and traded as low as $4.83. Sensus Healthcare shares last traded at $5.07, with a volume of 63,240 shares changing hands.

Analysts Set New Price Targets

A number of brokerages recently commented on SRTS. Maxim Group lifted their target price on shares of Sensus Healthcare from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. HC Wainwright boosted their target price on Sensus Healthcare from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, May 13th.

Sensus Healthcare Price Performance

The firm’s 50 day moving average is $5.13 and its 200 day moving average is $4.03. The company has a market capitalization of $83.10 million, a PE ratio of 17.48 and a beta of 1.00.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.18. The firm had revenue of $10.66 million for the quarter, compared to analysts’ expectations of $4.33 million. Sensus Healthcare had a net margin of 14.70% and a return on equity of 9.76%. During the same quarter in the previous year, the company earned ($0.12) earnings per share. As a group, analysts predict that Sensus Healthcare, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director John Heinrich sold 15,227 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $6.24, for a total transaction of $95,016.48. Following the completion of the transaction, the director now owns 59,940 shares in the company, valued at $374,025.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Sensus Healthcare

A number of institutional investors have recently bought and sold shares of SRTS. Sachetta LLC bought a new stake in Sensus Healthcare during the 4th quarter valued at approximately $247,000. Creekmur Asset Management LLC bought a new stake in shares of Sensus Healthcare during the fourth quarter valued at approximately $83,000. Finally, Hillsdale Investment Management Inc. purchased a new stake in Sensus Healthcare in the first quarter worth $155,000. 25.30% of the stock is owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.